A Phase I Pharmacokinetic And Pharmacodynamic Study Of PF-03446962 In Asian Patient With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2015
At a glance
- Drugs Ascrinvacumab (Primary)
- Indications Gastric cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 07 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov record